Načítá se...
The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy
Statins (HMG-CoA reductase inhibitors) lower low-density lipoprotein cholesterol (LDL-C) and prevent cardiovascular disease. However, there is wide individual variation in LDL-C response. Drugs targeting proprotein convertase subtilin/kexin type 9 (PCSK9) lower LDL-C and will be used with statins. P...
Uloženo v:
| Vydáno v: | Pharmacogenomics J |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4995153/ https://ncbi.nlm.nih.gov/pubmed/26902539 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2016.3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|